| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Article |
1 Columbia Presbyterian Medical Center, New York, NY;
2 Clinilabs Inc., New York, NY
3 E-mail: jonathansb{at}yahoo.com
Background—Reductions in heart rate (HR) with beta-blocker therapy have been associated with improvements in ejection fraction (EF). However, the relative contributions of HR reduction, positive inotropism, afterload reduction and reverse remodeling to improvements in EF are unknown.
Methods and Results—29 patients (63±12 years old) with NYHA II-III heart failure underwent serial measurements of LV volumes using three-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6 and 12 months after initiation of carvedilol. From these parameters, LV contractility (indexed by the end-systolic pressure-volume ratio), total peripheral resistance (TPR) and effective arterial elastance (Ea) were derived. Overall, EF increased by 7-percentage points after 6 months of therapy (from 25±9 to 32±9, p <0.0001). This change was due to an increase in stroke volume (p<0.001) with no significant change in end-diastolic volume (p=0.15). The EF change correlated with increased contractility, decreased HR and decreased TPR (p<0.003 in each case). In those patients whose EF increased at least 5 points, ~60% of the increase was due to HR reduction, ~30% was due to increased contractility and <20% was due to the decrease in TPR.
Conclusions—Decreased HR, improved chamber contractility and afterload reduction each contributed significantly to improved EF with carvedilol.
Key Words: contractility heart failure heart rate vasodilation ejection fraction
This article has been cited by other articles:
![]() |
D. Burkhoff Chasing the Elusive Pressure-Volume Relationships J. Am. Coll. Cardiol. Img., November 1, 2009; 2(11): 1282 - 1284. [Full Text] [PDF] |
||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |